Tech Company Financing Transactions
Cold Genesys Funding Round
On 3/19/2019, Cold Genesys raised $22 million in Series C funding from ORI Healthcare Fund and Perseverance Capital.
Transaction Overview
Company Name
Announced On
3/19/2019
Transaction Type
Venture Equity
Amount
$22,000,000
Round
Series C
Investors
ORI Healthcare Fund (Lead Investor) (Simone Song)
Proceeds Purpose
The financing will accelerate the growth of Cold Genesys' ongoing clinical programs and the continued advancement of its lead oncolytic immunotherapy CG0070, which has completed a Phase 2 study (BOND2) and demonstrated clinical safety and efficacy in over 100 patients to date for the treatment of Non-Muscle Invasive Bladder Cancer (NMIBC).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
400 Spectrum Center Dr. 2040
?Irvine, CA 92618
USA
?Irvine, CA 92618
USA
Phone
Undisclosed
Website
Email Address
Overview
Cold Genesys, Inc., a clinical-stage biopharmaceutical company developing oncolytic immunotherapies for cancer.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Arthur Kuan
Chief Scientific Officer
Paola Grandi
Controller
Amy Steele
VP - Bus. Development
Bing Kung
VP - Manufacturing
Bradley Grimm
Browse more venture capital transactions:
Prev: 3/19/2019: LeanData venture capital transaction
Next: 3/19/2019: AmplifAI venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on every notable VC transaction. VC investment data records on this site are derived from news reports and company announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs